IceCure Medical announced that data from an interim analysis of its ICESECRET kidney cancer trial were presented at the 3rd Annual Israeli Conference on Interventional Radiology in Tel Aviv, Israel on June 10, 2024. Dr. Avivit Shoham, Deputy Director of the Vascular and Interventional Radiology Unit at Beilinson Rabin Medical Center, presented a session on Cryotherapy of Renal Malignancies in Israel, which included data previously shared in December 2022 at the Urological Association Conference in Eilat, Israel. Professor Sarel Halachmi, the Principal Investigator of the ICESECRET clinical trial, said, “Cryoablation is a safe and effective, minimally invasive ablative approach for treating renal cell carcinoma presenting with tumors less than or equal to3 centimeters, resulting in shorter hospitalization than nephrectomy and minor side effects on the renal function and on hemoglobin levels. Further studies are needed to confirm cryoablation as a viable option to treat kidney lesions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Awaits FDA Review of ProSense® System
- IceCure Medical’s ProSense marketing clearance request to be reviewed by FDA
- IceCure Medical Sees Strong Q1 Growth, Awaits FDA Nod
- IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
- IceCure Medical reports Q1 EPS 8c vs. 8c last year